Cinvanti FDA Approval History
Last updated by Judith Stewart, BPharm on Oct 30, 2019.
FDA Approved: Yes (First approved November 9, 2017)
Brand name: Cinvanti
Generic name: aprepitant
Dosage form: Injection
Company: Heron Therapeutics, Inc.
Treatment for: Nausea/Vomiting, Chemotherapy Induced
Cinvanti (aprepitant) is a polysorbate 80 free, intravenous formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Cinvanti is indicated in adults, in combination with other antiemetic agents, for the prevention of:
- acute and delayed nausea and vomiting associated with initial and repeat courses of HEC (highly emetogenic cancer chemotherapy) including highdose cisplatin as a single-dose regimen.
- delayed nausea and vomiting associated with initial and repeat courses of MEC (moderately emetogenic cancer chemotherapy) as a single-dose regimen.
- nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen.
Development timeline for Cinvanti
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.